|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BUD13 |
Gene summary for BUD13 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BUD13 | Gene ID | 84811 |
| Gene name | BUD13 homolog | |
| Gene Alias | Cwc26 | |
| Cytomap | 11q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | Q9BRD0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84811 | BUD13 | LZE4T | Human | Esophagus | ESCC | 1.09e-02 | 1.37e-01 | 0.0811 |
| 84811 | BUD13 | LZE24T | Human | Esophagus | ESCC | 5.15e-10 | 2.92e-01 | 0.0596 |
| 84811 | BUD13 | P1T-E | Human | Esophagus | ESCC | 5.68e-05 | 2.16e-01 | 0.0875 |
| 84811 | BUD13 | P2T-E | Human | Esophagus | ESCC | 5.13e-17 | 2.23e-01 | 0.1177 |
| 84811 | BUD13 | P4T-E | Human | Esophagus | ESCC | 2.32e-19 | 3.90e-01 | 0.1323 |
| 84811 | BUD13 | P5T-E | Human | Esophagus | ESCC | 1.26e-07 | 1.75e-01 | 0.1327 |
| 84811 | BUD13 | P8T-E | Human | Esophagus | ESCC | 3.27e-07 | 1.26e-01 | 0.0889 |
| 84811 | BUD13 | P9T-E | Human | Esophagus | ESCC | 1.18e-04 | 1.44e-01 | 0.1131 |
| 84811 | BUD13 | P10T-E | Human | Esophagus | ESCC | 2.73e-10 | 2.40e-01 | 0.116 |
| 84811 | BUD13 | P11T-E | Human | Esophagus | ESCC | 1.13e-08 | 2.83e-01 | 0.1426 |
| 84811 | BUD13 | P12T-E | Human | Esophagus | ESCC | 3.88e-23 | 4.00e-01 | 0.1122 |
| 84811 | BUD13 | P15T-E | Human | Esophagus | ESCC | 1.10e-06 | 1.56e-01 | 0.1149 |
| 84811 | BUD13 | P16T-E | Human | Esophagus | ESCC | 1.50e-17 | 3.02e-01 | 0.1153 |
| 84811 | BUD13 | P17T-E | Human | Esophagus | ESCC | 4.41e-05 | 1.98e-01 | 0.1278 |
| 84811 | BUD13 | P20T-E | Human | Esophagus | ESCC | 6.24e-10 | 2.19e-01 | 0.1124 |
| 84811 | BUD13 | P21T-E | Human | Esophagus | ESCC | 1.27e-16 | 3.29e-01 | 0.1617 |
| 84811 | BUD13 | P22T-E | Human | Esophagus | ESCC | 1.00e-08 | 1.65e-01 | 0.1236 |
| 84811 | BUD13 | P23T-E | Human | Esophagus | ESCC | 1.63e-07 | 1.68e-01 | 0.108 |
| 84811 | BUD13 | P24T-E | Human | Esophagus | ESCC | 5.57e-06 | 1.25e-01 | 0.1287 |
| 84811 | BUD13 | P26T-E | Human | Esophagus | ESCC | 2.58e-20 | 3.97e-01 | 0.1276 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
| GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BUD13 | SNV | Missense_Mutation | novel | c.442N>A | p.Pro148Thr | p.P148T | Q9BRD0 | protein_coding | deleterious(0.03) | benign(0.169) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| BUD13 | insertion | Nonsense_Mutation | novel | c.1256_1257insATGTTTTCAACTATGACCTATATGTACATGATTTCCAAATCAATATT | p.Ala420CysfsTer5 | p.A420Cfs*5 | Q9BRD0 | protein_coding | TCGA-A8-A0A1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| BUD13 | SNV | Missense_Mutation | rs776700062 | c.1310N>A | p.Arg437Gln | p.R437Q | Q9BRD0 | protein_coding | tolerated(0.11) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| BUD13 | SNV | Missense_Mutation | novel | c.716N>G | p.Ser239Cys | p.S239C | Q9BRD0 | protein_coding | deleterious(0.03) | probably_damaging(0.921) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| BUD13 | SNV | Missense_Mutation | novel | c.1498G>T | p.Gly500Trp | p.G500W | Q9BRD0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| BUD13 | SNV | Missense_Mutation | c.1091N>A | p.Ser364Asn | p.S364N | Q9BRD0 | protein_coding | tolerated(0.39) | benign(0.003) | TCGA-EA-A78R-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| BUD13 | SNV | Missense_Mutation | rs766495135 | c.812N>T | p.Ser271Phe | p.S271F | Q9BRD0 | protein_coding | deleterious(0.01) | probably_damaging(0.923) | TCGA-IR-A3LF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| BUD13 | SNV | Missense_Mutation | c.767T>C | p.Leu256Pro | p.L256P | Q9BRD0 | protein_coding | tolerated(0.23) | benign(0.003) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| BUD13 | SNV | Missense_Mutation | rs753401362 | c.1229G>A | p.Arg410Gln | p.R410Q | Q9BRD0 | protein_coding | deleterious(0.04) | probably_damaging(0.964) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| BUD13 | SNV | Missense_Mutation | c.891N>T | p.Lys297Asn | p.K297N | Q9BRD0 | protein_coding | deleterious(0.02) | benign(0.255) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |